Disruption of the RPE caused by elevated inflammatory cytokines (like IL-17 or IL-23), as observed in patients with dyslipidemia, can activate other downstream inflammatory pathways (e.g. NF-kb signaling pathway). The gene discussed is IL37; the disease is metabolic syndrome.